Status:
UNKNOWN
Possible Protective Effect of Celecoxib Against Capecitabine Induced Hand and Foot Syndrome in Patients With Colorectal Cancer
Lead Sponsor:
Tanta University
Conditions:
Hand and Foot Syndrome
Erythrodysesthesia Syndrome
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
Colorectal cancer (CRC) is the third most common cancer and the second leading cause of malignancy-related mortality. Capecitabine has been approved for the treatment of colorectal cancer as first-lin...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Age: 18-65 years old.
- Gender: Male and female.
- Newly diagnosed colorectal cancer patients who are scheduled to receive capecitabine-based chemotherapy.
- Eastern Cooperative Oncology Group (ECOG) performance status \< 2
- Patients with adequate renal function (Sr. creatinine \< 1.2 mg/dl or eGFR ≥ 90 ml/min).
- Patients with adequate hepatic function (Sr. bilirubin \< 1.2 mg/dl).
- Exclusion criteria:
- Pregnant and lactating females.
- Patients with cardiovascular disease (congestive heart failure, cardiac arrhythmia, or coronary artery disease, …. etc.).
- History of H-Pylori infection.
- Patients with a known hypersensitivity to any of the used drugs.
- Patients with any contraindication to any of the used drugs.
Exclusion
Key Trial Info
Start Date :
April 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2025
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT05327751
Start Date
April 1 2022
End Date
April 1 2025
Last Update
April 14 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Pharmacy-Tanta University
Tanta, Egypt